Elapegademase-Lvlr
Brand name: Revcovi
Rank #435 of 500 drugs by total cost
$19.0M
Total Cost
52
Total Claims
$19.0M
Total Cost
4
Prescribers
$365K
Cost per Claim
0
Beneficiaries
52
30-Day Fills
$4.7M
Avg Cost/Provider
13
Avg Claims/Provider
About Elapegademase-Lvlr
Elapegademase-Lvlr (sold as Revcovi) was prescribed 52 times by 4 Medicare Part D providers in 2023, costing the program $19.0M. At $365K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 432 | Isavuconazonium Sulfate (Cresemba) | $19.2M | 3,050 |
| 433 | Paroxetine Hcl (Paroxetine Hcl) | $19.2M | 1,226,222 |
| 434 | Naloxone Hcl (Naloxone Hcl) | $19.0M | 232,875 |
| 435 | Elapegademase-Lvlr (Revcovi) | $19.0M | 52 |
| 436 | Methylprednisolone (Methylprednisolone) | $18.9M | 1,934,494 |
| 437 | Sacrosidase (Sucraid) | $18.5M | 1,517 |
| 438 | Enasidenib Mesylate (Idhifa) | $18.1M | 554 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology